This manuscript reviews the clinical evidence regarding single-dose intravenous (IV)
administration of the novel glutamatergic modulator racemic (R, S)-ketamine (hereafter …

The emerging roles of ketamine and esketamine as effective rapid-acting antidepressants
hold promise for patients suffering from treatment-resistant depression and/or major …

BackgroundPrior trials suggest that intravenous racemic ketamine is a highly effective for
treatment-resistant depression (TRD), but phase 3 trials of racemic ketamine are needed …

Introduction Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and
related substances show clinical promise but inadequately assess side effects. Measuring …

Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid
antidepressant effect, and intranasal (IN) esketamine has been recently approved in several …

Ketamine has recently emerged as a highly effective new treatment for people with treatment‐
resistant depression with rapid antidepressant effects. However, these effects are often short …

Abstract Background and Objective Affective disorders account for most cases of suicide.
The pharmacological arsenal to treat suicidality is limited and available agents take too long …

Objectives Rigorous clinical trials suggest ketamine is safe and well-tolerated in patients
with treatment-resistant depression (TRD). There is a paucity of data on the safety and …

Currently, only a limited number of interventions can rapidly relieve depressive
symptomatology in patients with major depressive disorder or bipolar disorder experiencing …

Background Suicidal patients often present to the emergency department, where specific
anti-suicidal treatment is lacking. Ketamine, a Glutamate modulator and a rapidly acting …